Global Severe Psoriasis API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 31, 2019--The “Severe Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
“Severe Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019” report provides comprehensive insights about marketed and Phase III products for Severe Psoriasis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.
Coverage of API manufacturers for Severe Psoriasis marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.
This report provides a comprehensive understanding of the emerging Phase III therapies for Severe Psoriasis which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2021.
Key Topics Covered:
1. Report Introduction
2. Severe Psoriasis: OverviewRisk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment
3. Comparative Analysis of Marketed and Emerging Products
4. Marketed TherapiesProduct Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Clinical Trials Regulatory Milestones Product Development Activities Product Details United States Europe Global Sales Assessment Historical Global Sales Forecasted Global Sales Patent Details Other marketed products
5. Emerging Therapies (Phase III)Product Description Research and Development Product Development Activities Forecasted Global Sales
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5gpp22/global_severe?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190131005799/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Psoriasis Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/31/2019 01:32 PM/DISC: 01/31/2019 01:32 PM